Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

Leukemia

Volumn 19, Issue 8, 2005, Pages 1306-1311

  Takeshita, Akihirot ^a   Shinjo, K ^a   Naito, K ^a   Matsui, H ^a   Sahara, N ^a   Shigeno, K ^a   Horii, T ^a   Shirai, N ^a   Maekawa, M ^a   Ohnishi, K ^a   Naoe, T ^b   Ohno, R ^c  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid (ATRA); Arsenic trioxide and drug resistance; Gemtuzumab ozogamicin (Myotarg)

Indexed keywords

ARSENIC TRIOXIDE; CD33 ANTIGEN; COMPLEMENTARY DNA; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PROPIDIUM IODIDE; RETINOIC ACID; THYMIDINE;

ARTICLE; BLAST CELL; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 23744476933     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403807     Document Type: Article

References (16)

1. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al., Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254.
2. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988-994.
3. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000; 14: 1436-1443.
4. Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002; 16: 813-819.
5. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994; 8: 968-973.
6. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH et al. Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222-4224.
7. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995-1999.
8. Gallaher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002; 16: 1940-1958.
9. Rybner C, Hillion J, Sahraoui T, Lanotte M, Botti J. All- trans retinoic acid down-regulates prion protein expression independently of granulocyte maturation. Leukemia 2002; 16: 940-948.
10. Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H et al. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000; 14: 1743-1750.
11. Takeshita A, Shinjo K, Naito K, Ohnishi K, Sugimoto Y, Yamakawa Y et al. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Br J Haematol 2000; 108: 90-92.
12. Takeshita A, Shinjo K, Naito K, Matsui H, Shigeno K, Nakamura S et al. P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells. Leukemia 2003; 17: 648-650.
13. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003; 17: 1454-1463.
14. Yang C-H, Kuo M-L, Chen J-C, Chen Y-C. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999; 81: 796-799.
15. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003; 102: 1466-1473.
16. Naito K, Takeshita A, Matsui H, Horii T, Maekawa M, Kitamura K et al. Multidrug resistance (MDR)-related protein 1 (MRP1) and lung resistance protein (LRP) are not the main drug resistance mechanisms of gemtuzumab ozogamicin (CMA-676) in AML. Hematol J 2002; 3: 1048a.